Valuation : Evofem Biosciences, Inc.

Market Cap 994K 857K 803K 733K 1.38M 95M 1.39M 9.53M 3.72M 47.95M 3.73M 3.65M 159M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.41M 47.75M 44.77M 40.87M 76.99M 5.3B 77.23M 531M 207M 2.67B 208M 204M 8.86B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day-8.54%
Current month+7.14%
1 month-0.92%
3 months+5.63%
6 months-18.48%
Current year-21.05%
1 week 0.01
Extreme 0.007
0.01
1 month 0.01
Extreme 0.0065
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.25
5 years 0
Extreme 0.0008
1,826.62
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 31/12/2017
Director of Finance/CFO 49 12/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 31/12/2017
Director/Board Member 58 31/12/2017
Date Insider Type Main position Quantity % Market Cap.
12/01/24 Sell

Chief Financial Officer

104 0.0010%
21/12/23 Sell

Director

10 0.0001%
13/04/23 Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-8.54%0.00%-25.00%-96.43% 994K
-0.13%-6.44%+60.47%+112.05% 1,047B
+0.85%-0.81%+52.77%+63.15% 646B
-1.03%-3.58%+22.87%+73.29% 451B
-1.46%-4.50%+37.43%+38.41% 355B
-0.72%-2.89%+21.86%+36.79% 291B
-1.19%-2.21%+1.35%+12.29% 252B
-1.05%-1.57%+51.40%+68.55% 234B
+0.08%-1.78%-17.64%-54.29% 203B
-2.14%-0.30%+29.42%+89.10% 181B
Average -1.54%-2.41%+23.50%+34.29% 365.93B
Weighted average by Cap. -0.48%-3.46%+38.66%+65.51%

Financials

2024 2025
Net sales 19.36M 16.69M 15.64M 14.28M 26.9M 1.85B 26.99M 186M 72.42M 934M 72.7M 71.12M 3.1B 20.18M 17.39M 16.31M 14.89M 28.04M 1.93B 28.13M 193M 75.48M 974M 75.78M 74.13M 3.23B
Net income -8.86M -7.63M -7.16M -6.53M -12.31M -847M -12.35M -84.93M -33.14M -427M -33.26M -32.54M -1.42B 391K 337K 316K 288K 543K 37.37M 545K 3.75M 1.46M 18.86M 1.47M 1.44M 62.55M
Net Debt 45.84M 39.5M 37.04M 33.81M 63.69M 4.38B 63.89M 439M 171M 2.21B 172M 168M 7.33B 54.42M 46.89M 43.97M 40.13M 75.61M 5.2B 75.85M 522M 204M 2.63B 204M 200M 8.71B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
28/08/26 US$0.007500 -8.54% 508,902
27/08/26 US$0.008200 +3.80% 254,129
26/08/26 US$0.007900 +11.27% 179,725
25/08/26 US$0.007100 +1.43% 249,981
24/08/26 US$0.007000 -6.67% 129,391

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock